ArticleClinical pharmacology and therapeutics2021

FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement.

Shashi Amur et al.PubMed ↗Publisher ↗

No numbers read from the abstract.